Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure

European Journal of Heart Failure

Volumn 3, Issue 3, 2001, Pages 351-357

  Shibata, Marcelo C ^a   Flather, Marcus D ^a,b   Wang, Duolao ^c  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Beta blocker; Heart failure; Meta analysis; Randomised controlled trial; Systematic review

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; CLINICAL TRIAL; DISABILITY; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT ADMISSION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034837574     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(01)00144-1     Document Type: Article

References (43)

1. Prevalence and mortality rate of congestive heart failure in the United States
2. The epidemiology of heart failure
3. Prevalence of heart failure in three general practices in north west London
4. An evaluation of the economic cost of heart failure to the National Health Service in the United Kingdom
5. Epidemiology of heart failure in United States
6. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta adrenergic blockade
7. Increased beta receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy
8. 2 adrenoceptors in human atrial myocardium
9. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials
10. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials
11. Beta-blocker therapy for congestive heart failure: A systematic overview and critical appraisal of the published trials
12. Clinical effects of beta-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomized trial
13. Beta-adrenergic blocking agents in heart failure: Benefits of vasodilating and non-vasodilating according to patients characteristics: A meta-analysis of clinical trials
14. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomised trial
15. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
16. Effects of control-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The Metoprolol CR/XL Randomized Intervention Trial In Congestive Heart Failure (MERIT-HF)
17. Why do we need systematic overviews of randomized trials?
18. Meta analysis in clinical trials
19. Why sources of heterogeneity in meta-analysis should be investigated
20. A randomized trial of low-dose beta blockade therapy for idiopathic dilated cardiomyopathy
21. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: A double-blind, randomized, placebo-controlled trial
22. Trattamento cronico della cardiomiopatia dilatativa con betablocanti
23. Usefulness of bucindolol in congestive heart failure
24. Beta blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy
25. Pilot study of cardiovascular effects of nebivolol in congestive heart failure
26. Long-term (3-month) effects of a new beta blocker (nebivolol) on cardiac performance in dilated cardiomyopathy
27. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy
28. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial
29. A randomized trial of beta blockade in heart failure: The cardiac insufficiency bisoprolol study
30. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy
31. Effect of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study
32. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy
33. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study
34. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure
35. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The Prospective Randomized Evaluation of Carvedilol in Symptoms and Exercise (PRECISE) trial
36. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
37. Carvedilol efficacy in severe heart failure
38. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure
39. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease
40. Design of the beta-blocker evaluation survival trial (BEST)
41. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
42. Design and methodology of the CAPRICORN trial - A randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction